Document registry — page 35
Every document the Institute has published, 1,639 in total, with its identifier, type, certainty rating and review date.
Documents
-
Phase 1 ascending dose, phase 1 study of Kisspeptin-10 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low03 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Larazotide acetate in mucosal barrier over as stated in the parent protocol. The Institute holds no…
Very low03 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Retatrutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low03 Nov 2023 -
Phase 1 ascending dose, phase 1 study of Cagrilintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low31 Oct 2023 -
Randomised crossover, phase 1 study of Semaglutide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low31 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Hexarelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low24 Oct 2023 -
Consultation on the rubric by which the Institute assesses a supplier dossier. The rubric scores documentary and analytical practice; it does not score product quality…
22 Oct 2023 -
Sterility testing of peptide preparations presented in sealed vials
High22 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Mazdutide in obesity randomising 248 participants over 24 weeks. Primary result: Mean change up to −15.4 %…
Moderate22 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of PT-141 (bremelanotide) in sexual dysfunction randomising 626 participants over 24 weeks. Primary result: A…
Moderate21 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of PT-141 (bremelanotide) in sexual dysfunction over as stated in the parent protocol. The Institute holds no…
Very low21 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of GHK-Cu in wound healing over 12 weeks. Primary result: Improvement in skin appearance measures in…
Low18 Oct 2023 -
Phase 1 ascending dose, phase 1 study of CJC-1295 in gh axis randomising Fewer than 100 participants over up to 49 days. Primary result: Sustained elevation of…
Low16 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low16 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low15 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Hexarelin in lean-mass preservation over as stated in the parent protocol. The Institute holds no reported…
Very low15 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Teduglutide in mucosal barrier randomising 86 participants over 24 weeks. Primary result: Response in 63 %…
Moderate14 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low14 Oct 2023 -
Observational, phase 2 study of Liraglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and publishes…
Very low14 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Liraglutide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low14 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Liraglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low14 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low13 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low11 Oct 2023 -
Recurrent upper-airway obstruction during sleep producing apnoeas and hypopnoeas, graded by the apnoea–hypopnoea index on polysomnography.
09 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds…
Very low09 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Retatrutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low09 Oct 2023 -
Consultation on the set of indications the Institute assesses against and the anchor outcome defined for each. The draft fixes one anchor outcome per indication so that…
08 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low08 Oct 2023 -
Randomised, open-label, active-controlled, phase 3 study of Dulaglutide in type 2 diabetes randomising 599 participants over 26 weeks. Primary result: Non-inferior to…
High07 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Exenatide in cardiovascular over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low07 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of Danuglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low06 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low06 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low06 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of PT-141 (bremelanotide) in sexual dysfunction randomising 630 participants over 24 weeks. Primary result…
Moderate05 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low05 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Retatrutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low04 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low03 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Cagrilintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low02 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low02 Oct 2023 -
Determination of chromatographic purity of synthetic peptides by reverse-phase high-performance liquid chromatography
High01 Oct 2023
page 35 of 41